TW201909926A - B7h3抗體-藥物偶聯物及其醫藥用途 - Google Patents
B7h3抗體-藥物偶聯物及其醫藥用途 Download PDFInfo
- Publication number
- TW201909926A TW201909926A TW107127102A TW107127102A TW201909926A TW 201909926 A TW201909926 A TW 201909926A TW 107127102 A TW107127102 A TW 107127102A TW 107127102 A TW107127102 A TW 107127102A TW 201909926 A TW201909926 A TW 201909926A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- seq
- cancer
- drug conjugate
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
??201710660432.9 | 2017-08-04 | ||
CN201710660432 | 2017-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201909926A true TW201909926A (zh) | 2019-03-16 |
Family
ID=65232283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107127102A TW201909926A (zh) | 2017-08-04 | 2018-08-03 | B7h3抗體-藥物偶聯物及其醫藥用途 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN109963591B (fr) |
TW (1) | TW201909926A (fr) |
WO (1) | WO2019024911A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018161872A1 (fr) * | 2017-03-06 | 2018-09-13 | 江苏恒瑞医药股份有限公司 | Anticorps anti-b7-h3, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée |
AU2019351427A1 (en) * | 2018-09-30 | 2021-04-15 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof |
CN115298220A (zh) * | 2020-03-24 | 2022-11-04 | 上海翰森生物医药科技有限公司 | 抗体-药物偶联物及其医药用途 |
CN115103691A (zh) * | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | 一种含抗体药物偶联物的药物组合物及其用途 |
WO2021190586A1 (fr) * | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | Conjugué d'anticorps anti-b7h3 et d'analogue d'exatecan et utilisation pharmaceutique de celui-ci |
WO2021190564A1 (fr) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | Conjugué anticorps-médicament et son utilisation médicale |
WO2022104692A1 (fr) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Anticorps modifié, conjugué anticorps-médicament et son utilisation |
CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
WO2022258691A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a |
WO2022258678A1 (fr) | 2021-06-09 | 2022-12-15 | Innate Pharma | Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a |
CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
CN113933373B (zh) * | 2021-12-16 | 2022-02-22 | 成都健数科技有限公司 | 一种利用质谱数据确定有机物结构的方法和系统 |
TW202400248A (zh) * | 2022-06-07 | 2024-01-01 | 中國大陸商映恩生物製藥(蘇州)有限公司 | 抗b7h3抗體-藥物結合物及其用途 |
CN117025547B (zh) * | 2023-10-08 | 2023-12-12 | 迈杰转化医学研究(苏州)有限公司 | 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116219A2 (fr) * | 2007-03-22 | 2008-09-25 | Sloan-Kettering Institute For Cancer Research | Utilisations de l'anticorps monoclonal 8h9 |
CA2834136C (fr) * | 2011-04-25 | 2018-04-17 | Daiichi Sankyo Company, Limited | Anticorps anti-b7-h3 |
BR122021014365B1 (pt) * | 2012-10-11 | 2022-07-05 | Daiichi Sankyo Company, Limited | Conjugado de anticorpo-fármaco, fármacos e composição farmacêutica compreendendo os mesmos, e uso |
JP6925264B2 (ja) * | 2014-08-27 | 2021-08-25 | メモリアル スローン ケタリング キャンサー センター | 抗体、組成物および使用 |
JP6905941B2 (ja) * | 2015-06-23 | 2021-07-21 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体 |
JP2018524313A (ja) * | 2015-06-23 | 2018-08-30 | バイエル ファーマ アクチエンゲゼルシャフト | キネシンスピンドルタンパク質(ksp)阻害剤の抗b7h3抗体との抗体薬物複合体 |
WO2017002776A1 (fr) * | 2015-06-29 | 2017-01-05 | 第一三共株式会社 | Procédé pour la préparation sélective d'un conjugué anticorps-médicament |
CN116284404A (zh) * | 2016-06-08 | 2023-06-23 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
CN109937212B (zh) * | 2017-03-31 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | B7-h3抗体、其抗原结合片段及其医药用途 |
CN110090306B (zh) * | 2018-01-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
CN110305213B (zh) * | 2018-11-09 | 2023-03-10 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
CN113121639B (zh) * | 2019-12-30 | 2024-05-14 | 江苏恒瑞医药股份有限公司 | 澳瑞他汀类似物及其偶联物、其制备方法及其应用 |
-
2018
- 2018-08-03 TW TW107127102A patent/TW201909926A/zh unknown
- 2018-08-03 CN CN201880004425.6A patent/CN109963591B/zh active Active
- 2018-08-03 WO PCT/CN2018/098480 patent/WO2019024911A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019024911A1 (fr) | 2019-02-07 |
CN109963591A (zh) | 2019-07-02 |
CN109963591B (zh) | 2023-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
KR102536145B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
TWI708788B (zh) | 雙特異性抗體 | |
JP2023002706A (ja) | 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法 | |
CA2798778C (fr) | Anticorps anti-trop-2 humain ayant une activite anticancereuse in vivo | |
CA2855699C (fr) | Anticorps anti-trop-2 humain presentant une activite antitumorale in vivo | |
US8841424B2 (en) | Humanized AXL antibodies | |
JP2020537509A (ja) | Tigit抗体、その抗原結合断片及びその医療用途 本願は、2019年9月29日に出願された出願番号cn201710908565.3に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 | |
JP2020504171A (ja) | 抗PD−1抗体との組み合わせのための抗Tim−3抗体 | |
WO2019091449A1 (fr) | Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée | |
TW202102546A (zh) | 密蛋白抗體及其應用 | |
CN112243443B (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
CN113906053B (zh) | 抗cea抗体及其应用 | |
JP2021531825A (ja) | 葉酸受容体アルファに特異的な抗体 | |
JP2022514693A (ja) | Muc18に特異的な抗体 | |
CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
TW202134286A (zh) | 抗gpc3抗體、其抗原結合片段及其醫藥用途 | |
JP2022514786A (ja) | Muc18に特異的な抗体 | |
JP2024514855A (ja) | Dll3に対する結合分子及びその使用 | |
CN113597432B (zh) | 抗EpCAM抗体及其应用 | |
US20220396618A1 (en) | Rage antibodies, fragments and uses thereof | |
WO2023190465A1 (fr) | Anticorps anti-sema7a humain | |
TWI836070B (zh) | 抗trop-2抗體、其抗原結合片段及其醫藥用途 | |
TWI837517B (zh) | 抗claudin 18.2和cd3的雙特異性抗體以及其用途 | |
WO2023109962A1 (fr) | Anticorps se liant au cd73 humain, son procédé de préparation et son utilisation |